Oleptro. Oleptro drug in the treatment of major depressive disorder has been recently approved by US FDA
Posted Feb 09 2010 1:41pm
US Food and Drug Administration (FDA) approved medication Oleptro (trazadone hydrochloride) in the form of extended release tablets for use once daily in the treatment of depressive disorders in adults. Oleptro was launched by the pharmaceutical company Labopharm.
Oletpro is approved to treat major depressive disorder (MDD). MDD is a common disease characterized by a number of social and somatic symptoms. The most significant of them include: reduced ability to concentrate attention, reduced self-esteem and self-confidence, feelings of of guilt and self-abasement; pessimistic vision of the future, ideas or actions that may lead to self-harm or suicide, disturbed sleep, decreased appetite. More than 14 million people in the U.S. alone suffer from major depressive disorder (MDD).
Oleptro extended release tablets are taken orally once a day at any time (morning or evening). A double-blind, randomized clinical investigation carried for a period of 8 weeks has proved the effectiveness and safety profile of the Oleptro.
The active ingredient of the medication is Trazadone which is currently made under the trade name Desyrel and is manufactured by Bristol-Myers Squibb. Trazadone works by increasing the amount of serotonin (neurotrasmitter) in the synaptic gap and thus relieves depression symptoms.
The most common Oleptro (trazadone) side effects include: drowsiness, dizziness, dry mouth, headache, nervousness, constipation, low blood pressure, weight loss, confusion, nausea, vomiting, and vision problems. In rare cases Oleptro may cause severe side effects.